Market Price

152.53 

-1.33 -0.9%

as of Jun 03 '20

52 Week Range:

101.36 164.90


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as migraine prevention. In addition, it offers immunology products for the treatment of rheumatoid arthritis and plaque psoriasis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia, and acute coronary syndrome. Further, the company provides animal health products, such as cattle feed additives; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and enteric diseases in swine and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent Bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; Nektar Therapeutics; NextCure, Inc.; Dicerna Pharmaceuticals; AC Immune SA; Avidity Biosciences, Inc.; and National Comprehensive Cancer Network. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Equity (BVPS) 8.29
10.78
13.00
12.88
15.12
15.91
13.77
14.16
13.54
12.36
3.53
growth rate 30.0% 20.6% -0.9% 17.4% 5.2% -13.5% 2.8% -4.4% -8.7% -71.4%
Earnings BIT 5,360.00
6,530.00
5,350.00
5,410.00
5,890.00
3,328.70
3,592.10
3,871.30
4,696.50
6,025.80
5,999.40
growth rate 21.8% -18.1% 1.1% 8.9% -43.5% 7.9% 7.8% 21.3% 28.3% -0.4%
Avg.PE 9.06
7.65
10.65
13.48
11.81
32.31
32.57
32.15
41.45
39.17
13.71
growth rate -15.6% 39.2% 26.6% -12.4% 173.6% 0.8% -1.3% 28.9% -5.5% -65.0%
ROA 15.28
17.34
13.45
12.01
13.45
6.60
6.62
7.36
-0.49
7.27
20.00
growth rate 13.5% -22.4% -10.7% 12.0% -50.9% 0.3% 11.2% -100.0% 100.0% 175.1%
ROE 53.25
46.20
33.49
28.89
28.92
14.49
16.09
19.16
-1.59
30.18
133.78
growth rate -13.2% -27.5% -13.7% 0.1% -49.9% 11.0% 19.1% -100.0% 100.0% 343.3%
ROIC 26.83
29.12
22.24
20.30
21.87
10.43
10.75
11.95
-0.68
13.91
41.94
growth rate 8.5% -23.6% -8.7% 7.7% -52.3% 3.1% 11.2% -100.0% 100.0% 201.5%
Cur. Ratio 1.90
2.09
1.60
1.55
1.47
1.09
1.53
1.37
1.32
1.73
1.16
growth rate 10.0% -23.4% -3.1% -5.2% -25.9% 40.4% -10.5% -3.7% 31.1% -33.0%
Quick Ratio 1.27
1.53
1.25
1.14
1.06
0.77
1.04
0.98
0.91
1.20
0.68
growth rate 20.5% -18.3% -8.8% -7.0% -27.4% 35.1% -5.8% -7.1% 31.9% -43.3%
Leverage 2.88
2.49
2.49
2.33
2.00
2.42
2.44
2.77
3.88
4.47
15.07
growth rate -13.5% 0.0% -6.4% -14.2% 21.0% 0.8% 13.5% 40.1% 15.2% 237.1%
Balance Sheet Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Acct.Receivable 3,343.30
3,493.80
4,237.90
3,888.30
4,022.80
3,792.20
4,058.50
4,732.10
5,234.60
5,696.30
5,523.10
growth rate 4.5% 21.3% -8.3% 3.5% -5.7% 7.0% 16.6% 10.6% 8.8% -3.0%
Acct.Payable 3,156.10
3,861.50
3,633.90
1,128.10
1,338.20
1,349.30
1,410.70
1,207.10
1,405.30
growth rate 22.4% -5.9% -69.0% 18.6% 0.8% 4.6% -14.4% 16.4%
Cur.Assets 12,486.50
14,840.00
14,248.20
13,038.70
13,104.70
11,928.30
12,573.60
15,101.40
19,202.10
20,549.60
13,709.60
growth rate 18.9% -4.0% -8.5% 0.5% -9.0% 5.4% 20.1% 27.2% 7.0% -33.3%
Total Assets 27,460.90
31,001.40
33,659.80
34,398.90
35,248.70
36,307.60
35,568.90
38,805.90
44,981.00
43,908.40
39,286.10
growth rate 12.9% 8.6% 2.2% 2.5% 3.0% -2.0% 9.1% 15.9% -2.4% -10.5%
Cash 4,462.90
5,993.20
5,922.50
4,018.80
3,830.20
3,871.60
3,666.40
4,582.10
6,536.20
7,320.70
2,337.50
growth rate 34.3% -1.2% -32.1% -4.7% 1.1% -5.3% 25.0% 42.7% 12.0% -68.1%
Inventory 2,849.90
2,517.70
2,299.80
2,643.80
2,928.80
2,740.00
3,445.80
3,561.90
4,458.30
3,098.10
3,190.70
growth rate -11.7% -8.7% 15.0% 10.8% -6.5% 25.8% 3.4% 25.2% -30.5% 3.0%
Cur.Liabilities 6,568.10
7,101.40
8,930.90
8,389.50
8,916.60
9,741.00
8,229.60
10,986.60
14,535.90
11,888.10
11,775.20
growth rate 8.1% 25.8% -6.1% 6.3% 9.3% -15.5% 33.5% 32.3% -18.2% -1.0%
Liabilities 17,937.20
18,581.10
20,124.20
19,625.00
17,608.00
20,919.50
20,978.60
24,725.40
33,313.10
32,999.30
36,587.00
growth rate 3.6% 8.3% -2.5% -10.3% 18.8% 0.3% 17.9% 34.7% -0.9% 10.9%
LT Debt 6,634.70
6,770.50
5,464.70
5,519.40
4,200.30
5,333.50
7,972.80
8,368.30
9,977.00
9,241.20
13,829.80
growth rate 2.1% -19.3% 1.0% -23.9% 27.0% 49.5% 5.0% 19.2% -7.4% 49.7%
Equity 9,523.70
12,420.30
13,541.70
14,765.20
17,631.40
15,373.20
14,571.30
14,007.70
11,592.20
9,828.70
2,606.90
growth rate 30.4% 9.0% 9.0% 19.4% -12.8% -5.2% -3.9% -17.2% -15.2% -73.5%
Common Shares 1,098.00
1,106.00
1,114.00
1,117.00
1,085.00
1,074.00
1,066.00
1,062.00
1,052.00
1,034.00
936.00
growth rate 0.7% 0.7% 0.3% -2.9% -1.0% -0.7% -0.4% -0.9% -1.7% -9.5%
Cash Flow Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Capital Expenditures 747.30
669.70
672.00
905.40
1,012.10
1,162.60
1,066.20
1,037.00
1,076.80
1,210.60
1,033.90
growth rate -10.4% 0.3% 34.7% 11.8% 14.9% -8.3% -2.7% 3.8% 12.4% -14.6%
Cash Dividends 2,152.10
2,165.30
2,180.10
2,187.40
2,120.70
2,101.20
2,127.30
2,158.50
2,192.10
2,311.80
2,409.80
growth rate 0.6% 0.7% 0.3% -3.1% -0.9% 1.2% 1.5% 1.6% 5.5% 4.2%
Cash From OA 4,335.50
6,856.80
7,234.50
5,304.80
5,735.00
4,458.40
2,964.60
4,851.00
5,615.60
5,524.50
4,836.60
growth rate 58.2% 5.5% -26.7% 8.1% -22.3% -33.5% 63.6% 15.8% -1.6% -12.5%
FCF per Share 3.17
5.13
5.25
3.81
4.21
2.87
1.39
2.22
3.54
2.83
2.78
growth rate 61.8% 2.3% -27.4% 10.5% -31.8% -51.6% 59.7% 59.5% -20.1% -1.8%
Sale Purchase of Stock -721.10
-1,698.10
-800.00
-749.50
-600.10
-299.80
growth rate 0.0% 0.0% 0.0% 0.0% 0.0%
FCF 3,481.00
5,670.00
5,542.00
4,261.00
4,641.00
2,801.00
1,146.00
3,759.00
3,452.00
2,506.00
3,483.00
growth rate 62.9% -2.3% -23.1% 8.9% -39.7% -59.1% 228.0% -8.2% -27.4% 39.0%
Income Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Sales 21,836.00
23,076.00
24,286.50
22,603.40
23,113.10
19,615.60
19,958.70
21,222.10
19,973.80
21,493.30
22,319.50
growth rate 5.7% 5.3% -6.9% 2.3% -15.1% 1.8% 6.3% -5.9% 7.6% 3.8%
Op.Income 5,587.30
6,525.20
4,347.70
4,088.60
4,684.80
3,328.70
3,592.10
3,871.30
4,696.50
6,025.80
5,999.40
growth rate 16.8% -33.4% -6.0% 14.6% -29.0% 7.9% 7.8% 21.3% 28.3% -0.4%
IBT 5,357.80
6,525.20
5,349.50
5,408.20
5,889.30
3,000.30
2,790.00
3,374.00
2,304.80
3,680.10
5,265.90
growth rate 21.8% -18.0% 1.1% 8.9% -49.1% -7.0% 20.9% -31.7% 59.7% 43.1%
Net Income 4,328.80
5,069.50
4,347.70
4,088.60
4,684.80
2,390.50
2,408.40
2,737.60
-204.10
3,232.00
8,318.40
growth rate 17.1% -14.2% -6.0% 14.6% -49.0% 0.8% 13.7% -100.0% 100.0% 157.4%
EPS 3.94
4.58
3.90
3.66
4.32
2.23
2.26
2.58
-0.19
3.13
8.89
growth rate 16.2% -14.9% -6.2% 18.0% -48.4% 1.4% 14.2% -100.0% 100.0% 184.0%
Gross Profit 17,589.00
18,709.80
19,218.60
17,806.90
18,205.00
14,683.10
14,921.50
15,512.00
15,526.10
16,811.60
17,598.30
growth rate 6.4% 2.7% -7.4% 2.2% -19.4% 1.6% 4.0% 0.1% 8.3% 4.7%
R&D 4,326.50
4,884.20
5,020.80
5,278.10
5,531.30
4,733.60
4,796.40
5,310.30
5,096.20
5,051.20
5,595.00
growth rate 12.9% 2.8% 5.1% 4.8% -14.4% 1.3% 10.7% -4.0% -0.9% 10.8%

Quarterly Statements

Item Name Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Earnings BIT 1,261.80
1,573.10
1,560.60
1,603.90
1,747.60
growth rate 24.7% -0.8% 2.8% 9.0%
Balance Sheet Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Acct.Receivable 5,105.90
5,555.50
5,481.60
5,523.10
6,320.00
growth rate 8.8% -1.3% 0.8% 14.4%
Acct.Payable 1,168.10
1,198.90
1,114.90
1,405.30
1,207.70
growth rate 2.6% -7.0% 26.1% -14.1%
Cur.Assets 12,597.50
13,454.50
12,661.80
13,709.60
13,994.20
growth rate 6.8% -5.9% 8.3% 2.1%
Total Assets 38,006.80
38,666.40
37,893.10
39,286.10
41,102.80
growth rate 1.7% -2.0% 3.7% 4.6%
Cash 2,036.40
2,290.20
1,563.80
2,337.50
1,699.00
growth rate 12.5% -31.7% 49.5% -27.3%
Inventory 3,055.20
3,181.10
3,101.30
3,190.70
3,102.40
growth rate 4.1% -2.5% 2.9% -2.8%
Cur.Liabilities 11,236.10
11,855.40
10,828.60
11,775.20
12,610.20
growth rate 5.5% -8.7% 8.7% 7.1%
Liabilities 35,441.80
35,809.10
34,430.80
36,587.00
37,905.60
growth rate 1.0% -3.9% 6.3% 3.6%
LT Debt 13,645.50
13,738.70
13,744.70
13,829.80
14,383.40
growth rate 0.7% 0.0% 0.6% 4.0%
Equity 2,480.30
2,780.50
3,382.50
2,606.90
3,078.80
growth rate 12.1% 21.7% -22.9% 18.1%
Common Shares 607.10
603.70
600.40
598.80
598.10
growth rate -0.6% -0.6% -0.3% -0.1%
Cash Flow Statement Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Capital Expenditures 203.70
240.30
263.40
326.50
258.30
growth rate 18.0% 9.6% 24.0% -20.9%
Cash Dividends 637.20
598.00
587.40
587.20
671.30
growth rate -6.2% -1.8% 0.0% 14.3%
Cash From OA 311.30
1,051.50
1,510.10
1,963.70
382.40
growth rate 237.8% 43.6% 30.0% -80.5%
Sale Purchase of Stock
growth rate
FCF 107.60
811.20
1,246.70
1,637.20
124.10
growth rate 653.9% 53.7% 31.3% -92.4%
Income Statement Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Sales 5,092.20
5,636.70
5,476.60
6,114.00
5,859.80
growth rate 10.7% -2.8% 11.6% -4.2%
Op.Income 1,261.80
1,573.10
1,560.60
1,603.90
1,747.60
growth rate 24.7% -0.8% 2.8% 9.0%
IBT 731.10
1,465.90
1,405.80
1,663.10
1,679.90
growth rate 100.5% -4.1% 18.3% 1.0%
Net Income 4,241.60
1,327.20
1,253.90
1,495.70
1,456.50
growth rate -68.7% -5.5% 19.3% -2.6%
EPS
growth rate
Gross Profit 3,953.50
4,511.80
4,301.60
4,831.40
4,644.70
growth rate 14.1% -4.7% 12.3% -3.9%
R&D 1,230.50
1,402.20
1,380.90
1,581.40
1,392.10
growth rate 14.0% -1.5% 14.5% -12.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (17.55)

YOY Growth Grade:

F (16.26)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 13.71 18.48 17.12
EPS / Growth 2.8% 8.26 11.4%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 1.9% 1.9%
Future PE 2.00 11.54 11.54
Future EPS 9.12 9.96 9.96
Value Price
MOS %
4.51
-97.0%
28.43
-81.4%
28.43
-81.4%
MOS Price 2.25 14.22 14.22
IRT 16.88 15.73 15.73

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.